Bao Haiwei, Dai Lulu, Wang Huiyang, Jiang Tianan
Department of Ultrasound Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310000, Zhejiang, China.
Int J Pharm X. 2024 Nov 4;8:100300. doi: 10.1016/j.ijpx.2024.100300. eCollection 2024 Dec.
Acute rejection (AR) remains a pivotal complication and leading cause of mortality within the first year following heart transplantation (HT). In this study, we assessed the impact of ultrasound-targeted microbubbles loaded with sirolimus (SIR-MBs) on AR in a rat HT model and delved into the underlying mechanisms. We established a rat abdominal ectopic HT model, which was stratified into three groups receiveing the PBS, SIR-MBs + ultrasound-targeted microbubble destruction (UTMD), and sirolimus, respectively. The protective effects of each treatments on survival rate, inflammatory response, autophagy and TGF-β1-Smad signaling pathway-related proteins were evaluted. Additionally, rescue experiment was performed adding the autophagy inhibitor or TGF-β1 agonist in combination therapy. UTMD combined SIR-MBs mediated 15-fold higher local drug concentration compared to direct sirolimus administration. The infiltration of inflammatory cells in the transplanted hearts indicated that SIR-MBs combined with UTMD were effective in mitigating the inflammatory response, achieving levels significantly lower than those observed in the sirolimus group. Furthermore, after SIR-MBs combined with UTMD treatment, the expression levels of TGF-β1-Smad signaling pathway-related proteins in heart tissues also showed a significant decrease compared to the model control group. Conversely, the expressions of autophagy proteins LC3-II, Beclin-1 and β-arrestin showed an up-regulated trend. Rescue experiments also revealed that the enhancement in survival trends was markedly suppressed following the administration of CsA or SRI-011381, respectively. Collectively, our findings suggest that SIR-MBs combined with UTMD augment the local treatment efficacy for AR in rat HT models by inhibiting the TGF-β1-Smad signaling pathway, promoting autophagy, and alleviating inflammation.
急性排斥反应(AR)仍然是心脏移植(HT)后第一年的关键并发症和主要死亡原因。在本研究中,我们评估了负载西罗莫司的超声靶向微泡(SIR-MBs)对大鼠HT模型中AR的影响,并深入探讨了其潜在机制。我们建立了大鼠腹部异位HT模型,将其分为三组,分别接受磷酸盐缓冲液(PBS)、SIR-MBs+超声靶向微泡破坏(UTMD)和西罗莫司。评估了每种治疗对存活率、炎症反应、自噬以及转化生长因子-β1(TGF-β1)-Smad信号通路相关蛋白的保护作用。此外,在联合治疗中添加自噬抑制剂或TGF-β1激动剂进行了挽救实验。与直接给予西罗莫司相比,UTMD联合SIR-MBs介导的局部药物浓度高15倍。移植心脏中炎症细胞的浸润表明,SIR-MBs与UTMD联合可有效减轻炎症反应,达到显著低于西罗莫司组的水平。此外,与模型对照组相比,SIR-MBs与UTMD联合治疗后,心脏组织中TGF-β1-Smad信号通路相关蛋白的表达水平也显著降低。相反,自噬蛋白LC3-II、Beclin-1和β-抑制蛋白的表达呈上调趋势。挽救实验还表明,分别给予环孢素A(CsA)或SRI-011381后,生存趋势的增强明显受到抑制。总体而言,我们的研究结果表明,SIR-MBs与UTMD联合通过抑制TGF-β1-Smad信号通路、促进自噬和减轻炎症,增强了大鼠HT模型中AR的局部治疗效果。